Profender Spot-On For Cats 11.1-17.6 lbs (5-8 kg)

Description

Profender Spot-On For Cats 11.1-17.6 lbs (5-8 kg) is a single-dose spot-on dewormer containing 24 mg emodepside and 96 mg praziquantel, formulated to address hookworm, roundworm, and tapeworm infections through a single dermal application at the base of the skull.

Recommended for

Cats and kittens weighing 11.1–17.6 lbs (5–8 kg) from 8 weeks of age.

Indication/Coverage

For cats suffering from, or at risk from, mixed intestinal worm infections, Profender Spot-On For Cats 11.1–17.6 lbs covers the following parasitic conditions:

• Hookworm treatment: Clears Ancylostoma tubaeforme infections across adult, immature adult, and fourth-stage larval (L4) stages via systemic distribution of transdermally absorbed emodepside.
• Roundworm treatment: Eliminates Toxocara cati adults, immature adults, and L4 larvae, reducing the risk of ongoing gastrointestinal burden from developing worm stages.
• Tapeworm treatment: Eradicates Dipylidium caninum adults and Taenia taeniaeformis adults through the direct cestocidal action of praziquantel on the parasite’s tegument.

Key Benefits

The following actions are documented on the Elanco product label and field study data for Profender Spot-On For Cats 11.1–17.6 lbs:

• Large-cat dosing: The large pipette (1.12 mL) delivers 24 mg emodepside and 96 mg praziquantel, calibrated to the 5–8 kg weight band with a minimum dose of 3 mg/kg emodepside.
• Triple parasite coverage: One application targets hookworms, roundworms, and tapeworms simultaneously, removing the need to administer separate anthelmintic products for nematode and cestode infections.
• Transdermal systemic action: Emodepside is absorbed through the skin and distributed systemically to reach gastrointestinal parasites without oral ingestion, bypassing the GI tract entirely as a route of delivery.
• Larval stage efficacy: Both emodepside and praziquantel act against immature adults and larval stages of the labeled nematodes, not only established adult worms, limiting re-establishment from developing populations.
• Single-dose treatment: One pipette application is effective without a follow-up dose. Re-treatment is appropriate only upon confirmed re-infection, and not before 30 days have elapsed since the preceding application.
• Topical route for resistant cats: Spot-on application removes the handling stress associated with oral dosing. Cats that consistently spit out tablets or resist oral syringes can be treated without the compliance issues that oral forms carry.
• Established multi-drug safety: Field data confirms Profender was used safely in cats concurrently receiving flea and tick products, NSAIDs, antimicrobials, anxiolytics, steroids, cardiac medications, and other concurrent treatments.

Caution

Hazards to Humans

Keep out of reach of children. Avoid direct contact with skin, eyes, and clothing during application. Wash hands thoroughly with soap and warm water after handling. Children should not contact the application site for 24 hours post-dosing. If accidental ingestion or eye exposure occurs, flush with water and contact a poison control center.

Hazards to Domestic Animals

For external use only. Do not administer to cats under 8 weeks of age or weighing less than 2.2 lbs (1 kg). Cats used for breeding, currently pregnant, or in lactation should receive this product only under veterinary guidance, as safety in these groups has not been established. Use in debilitated or sick animals requires prior veterinary assessment. Safety in heartworm-positive cats has not been evaluated; consult a veterinarian before use in such animals.

Possible Side Effects

Monitor your cat in the hours following application, noting any behavioral or physical changes at and away from the application site. The adverse reactions below were documented in field studies and post-approval reporting; all field study reactions were self-limiting.

Dermal reactions: Licking or excessive grooming (3.0%), scratching at the site (2.5%), and hair loss, dermatitis, pyoderma, edema, or erythema at the application area have been observed.

Gastrointestinal signs: Salivation, vomiting, and diarrhea have each been recorded at low incidence in field study data, predominantly linked to oral exposure through licking.

Systemic signs: Lethargy, ataxia, hypersalivation, fever, hyperactivity, nervousness, mydriasis, and twitching have been reported in post-approval settings. In isolated cases, seizures, paresis, and death have been listed as outcomes in FDA CVM post-approval adverse event reports. The full listing is available at fda.gov/reportanimalae.